达比加群酯致抗凝剂相关肾病1例  

Anticoagulant related nephropathy induced by dabigatranet exilate:one case report

作　　者：谌甜甜 邹娟 魏安华[1] CHEN Tiantian;ZOU Juan;WEI Anhua(Department of Pharmacy,Tongji Hospital,Tongji Medical College,Huazhong University of Science&Technology,Hubei Wuhan 430033,China;Department of Pharmacy,Hunan Want Want Hospital,Hunan Changsha 410016,China;Department of Pharmacy,Tianyou Hospital,Wuhan University of Science&Technology,Hubei Wuhan 430064,China)

机构地区：[1]华中科技大学同济医学院附属同济医院药学部,湖北武汉430033 [2]湖南旺旺医院药学部,湖南长沙410016 [3]武汉科技大学附属天佑医院药学部,湖北武汉430064

出　　处：《中国医院药学杂志》2024年第13期1600-1602,共3页Chinese Journal of Hospital Pharmacy

摘　　要：抗凝剂相关肾病(anticoagulant-related nephropathy,ARN)是一种由抗凝剂过度抗凝引起的药品不良反应,显著增加患者死亡风险。新型口服抗凝剂此类报道少见,易被临床误诊或忽视。本文报道1例阵发性心房颤动患者接受达比加群酯等药物治疗后出现急性肾损伤,伴有血尿、蛋白尿及凝血功能异常的罕见病例,分析其诱发ARN的高危因素,通过停药、护肾、促排等治疗后成功好转,同时对国内外报道文献进行梳理,以期为ARN的诊断与处置提供借鉴。Anticoagulant-related nephropathy(ARN)is an adverse drug reaction of excessive anticoagulation.With a high mortality rate,it may be easily misdiagnosed or ignored in clinical practices.Novel oral anticoagulants have been rarely mentioned.Here the authors reported one case of paroxysmal atrial fibrillation.After the patient taking dabigatran etexilate and other drugs,acute kidney injury was associated with hematuria,proteinuria and abnormal coagulation.The high-risk factors were discussed for ARN induced by dabigatran etexilate.After dabigatran etexilate withdrawal,kidney supportive care and excretion enhancement,he recovered eventually.Both domestic and foreign literatures were reviewed for providing references for proper managements of ARN.

关 键 词：达比加群酯 抗凝剂相关肾病 急性肾损伤 药品不良反应 

分 类 号：R969.3[医药卫生—药理学]